Get the Stockscreener App
70.39
0.01%
0.01
Axonics Inc stock is traded at $70.39, with a volume of 319.06K.
It is up +0.01% in the last 24 hours and up +1.09% over the past month.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
See More
Previous Close:
$70.38
Open:
$70.36
24h Volume:
319.06K
Relative Volume:
0.87
Market Cap:
$3.60B
Revenue:
$408.81M
Net Income/Loss:
$-1.71M
P/E Ratio:
-281.56
EPS:
-0.25
Net Cash Flow:
$18.92M
1W Performance:
+0.21%
1M Performance:
+1.09%
6M Performance:
+4.62%
1Y Performance:
+29.54%
1-Day Range:
$70.33
$70.43
1-Week Range:
$70.07
$70.48
52-Week Range:
$49.70
$70.53
Axonics Inc Stock (AXNX) Company Profile
Name
Axonics Inc
Sector
Industry
Phone
949-396-6322
Address
26 TECHNOLOGY DRIVE, IRVINE, CA
Axonics Inc Stock (AXNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jul-13-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-23-23 | Initiated | CL King | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Upgrade | Needham | Hold → Buy |
| Oct-21-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Oct-10-22 | Downgrade | Needham | Buy → Hold |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jul-12-21 | Initiated | Barclays | Overweight |
| Jun-28-21 | Reiterated | Needham | Buy |
| Nov-05-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Aug-07-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Nov-01-19 | Initiated | Piper Jaffray | Overweight |
| Oct-21-19 | Initiated | Barclays | Overweight |
| Sep-17-19 | Initiated | SVB Leerink | Outperform |
| Sep-09-19 | Reiterated | Needham | Buy |
| Sep-03-19 | Initiated | Needham | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Nov-26-18 | Initiated | BofA/Merrill | Buy |
| Nov-26-18 | Initiated | Morgan Stanley | Overweight |
| Nov-26-18 | Initiated | SunTrust | Buy |
| Nov-26-18 | Initiated | Wells Fargo | Outperform |
View All
Axonics Inc Stock (AXNX) Latest News
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Oak Ridge Investments LLC - MarketBeat
Long Term Trading Analysis for (AXNX) - Stock Traders Daily
Axonics, Inc. (NASDAQ:AXNX) Short Interest Update - MarketBeat
Axonic’s stock soars after cash buyout deal with Boston Scientific valued at $3.7 billion - MSN
Axonics, Inc. (NASDAQ:AXNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
How to Take Advantage of moves in (AXNX) - Stock Traders Daily
Axonics Wins Australian Approval For Fourth-Generation Rechargeable SNM System - MPO-mag
Axonics Wins Australian Approval for Fourth-Generation Rechargeable SNM System - MPO-mag
Axonics, Inc. (NASDAQ:AXNX) Holdings Trimmed by Kapitalo Investimentos Ltda - MarketBeat
Axonics, Inc. (AXNX): Strong Growth and Global Momentum in 2024 - Insider Monkey
Sei Investments Co. Has $237,000 Stock Position in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics stock soars to 52-week high, reaches $69.92 By Investing.com - Investing.com South Africa
Axonics (NASDAQ:AXNX) Sets New 12-Month HighStill a Buy? - MarketBeat
Axonics stock soars to 52-week high, reaches $69.92 - Investing.com
Axonics gains after Boston Scientific says it will end use of Coaptite on Nov. 1 - Seeking Alpha
Objective long/short (AXNX) Report - Stock Traders Daily
Horizon Health Urology recieves high honor - MSN
Healthcare of Ontario Pension Plan Trust Fund Acquires Shares of 224,300 Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics CFO sells over $205k in company stock By Investing.com - Investing.com Australia
Kari Leigh Keese Sells 2,961 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock - MarketBeat
Axonics CFO sells over $205k in company stock - Investing.com India
The top 10 neurotech stories of the year so far - Mass Device
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device - MSN
Millennium Management LLC Has $51.14 Million Stock Position in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics gains after win in trial in patent dispute with Medtronic - MSN
Renaissance Technologies LLC Sells 140,200 Shares of Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia - MSN
(AXNX) On The My Stocks Page - Stock Traders Daily
Mackenzie Financial Corp Cuts Stake in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device - Benzinga
Axonics stock hits 52-week high at $69.91 amid robust growth - Investing.com
Axonics stock hits 52-week high at $69.91 amid robust growth By Investing.com - Investing.com South Africa
Dark Forest Capital Management LP Makes New Investment in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Axonics’ sacral neuromodulation device cleared in Australia - Medical Device Network
Axonics, Inc. (NASDAQ:AXNX) Receives $69.57 Consensus Target Price from Brokerages - MarketBeat
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia - StockTitan
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic - MSN
Xponance Inc. Has $4.57 Million Stake in The AES Co. (NYSE:AES) - MarketBeat
Absolute Gestao de Investimentos Ltda. Makes New $32.68 Million Investment in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
AxoGen (NASDAQ:AXGN) Upgraded by StockNews.com to Buy - Defense World
Axos Financial, Inc. to Announce First Quarter Fiscal 2025 Results on October 30, 2024 - Business Wire
Wedbush Trims Axos Financial (NYSE:AX) Target Price to $75.00 - Defense World
Axos Financial price target lowered to $75 from $80 at Wedbush - TipRanks
Metric Deep Dive: Understanding AXT Inc (AXTI) Through its Ratios - The Dwinnex
Epoch Investment Partners Inc. Has $2.45 Million Stake in Axos Financial, Inc. (NYSE:AX) - MarketBeat
P Schoenfeld Asset Management LP Acquires 170,000 Shares of Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Glazer Capital LLC Invests $6.64 Million in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Raymond Cohen: Improving Patients’ Quality of Life - Orange County Business Journal
The top 10 urology device stories of 2024 so far - Mass Device
Hsbc Holdings PLC Raises Stock Position in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
First Eagle Investment Management LLC Has $12.21 Million Position in Axos Financial, Inc. (NYSE:AX) - Defense World
Axonics Inc Stock (AXNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axonics Inc Stock (AXNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| COHEN RAYMOND W | Chief Executive Officer |
Jul 24 '24 |
Option Exercise |
22.94 |
103,896 |
2,382,878 |
292,731 |
| Sama Rinda | Chief Operating Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
28,000 |
0 |
83,854 |
| Noblett Karen | Chief Medical Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
27,500 |
0 |
45,716 |
| Noblett Karen | Chief Medical Officer |
Jan 31 '24 |
Sale |
67.74 |
11,288 |
764,603 |
34,428 |
| Woock John | EVP, Chief Mktg/Strtgy Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
28,000 |
0 |
93,302 |
| Woock John | EVP, Chief Mktg/Strtgy Officer |
Jan 31 '24 |
Sale |
67.74 |
15,899 |
1,076,933 |
77,403 |
| Ford Alfred J Jr | Chief Commercial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
25,500 |
0 |
60,065 |
| Ford Alfred J Jr | Chief Commercial Officer |
Jan 31 '24 |
Sale |
67.74 |
16,615 |
1,125,432 |
43,450 |
| Keese Kari Leigh | Chief Financial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
6,167 |
0 |
46,812 |
| Keese Kari Leigh | Chief Financial Officer |
Jan 31 '24 |
Sale |
67.74 |
3,489 |
236,331 |
43,323 |
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):